LY3437943 + Ethinyl Estradiol + Drospirenone

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Overweight

Conditions

Overweight

Trial Timeline

Sep 12, 2023 → Jul 11, 2024

NCT ID

NCT06039826

About LY3437943 + Ethinyl Estradiol + Drospirenone

LY3437943 + Ethinyl Estradiol + Drospirenone is a phase 1 stage product being developed by Eli Lilly for Overweight. The current trial status is completed. This product is registered under clinical trial identifier NCT06039826. Target conditions include Overweight.

What happened to similar drugs?

1 of 20 similar drugs in Overweight were approved

Approved (1) Terminated (0) Active (19)

✅AripiprazoleBristol Myers SquibbApproved

🔄Eloralintide + PlaceboEli LillyPhase 3

🔄Tirzepatide + PlaceboEli LillyPhase 3

🔄Maridebart cafraglutide + PlaceboAmgenPhase 3

🔄Semaglutide + Semaglutide PlaceboNovo NordiskPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06039826	Phase 1	Completed	Sep 12, 2023	Jul 11, 2024	Overweight

Competing Products

20 competing products in Overweight

See all competitors

Product	Company	Stage	Hype Score
TERN-601	Terns Pharmaceuticals	Phase 2	32
LY3457263 + Tirzepatide + Placebo	Eli Lilly	Phase 1	29
LY3305677 + Placebo	Eli Lilly	Phase 1	29
LY3537031 + Placebo	Eli Lilly	Phase 1	33
Tirzepatide + Lisdexamfetamine Dimesylate + Placebo (oral) + Placebo (injection)	Eli Lilly	Phase 2	42
Eloralintide + Placebo	Eli Lilly	Phase 3	47
LY4064912 + LY4064912 + Placebo + Placebo	Eli Lilly	Phase 1	36
Tirzepatide + Acetaminophen	Eli Lilly	Phase 1	29
Tirzepatide + Placebo	Eli Lilly	Phase 2	39
Eloralintide + Placebo	Eli Lilly	Phase 3	47
LY3437943 + Placebo	Eli Lilly	Phase 1	29
LY3502970 + Placebo	Eli Lilly	Phase 1	29
Tirzepatide + Placebo	Eli Lilly	Phase 3	44
Eloralintide and Tirzepatide + Eloralintide	Eli Lilly	Phase 1	29
Tirzepatide + Placebo	Eli Lilly	Phase 3	40
LY3541105 + Placebo	Eli Lilly	Phase 1	29
Retatrutide + Placebo	Eli Lilly	Phase 2	35
LY4167586 + Placebo + LY4167586	Eli Lilly	Phase 1	36
AZD9550 + AZD6234 + Placebo comparator	AstraZeneca	Phase 2	39
pramlintide acetate + sibutramine + phentermine + placebo	AstraZeneca	Phase 2	35